CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
46.28
-0.98 (-2.07%)
Nov 21, 2024, 11:39 AM EST - Market open
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for CRSP stock have an average target of 73.69, with a low estimate of 30 and a high estimate of 105. The average target predicts an increase of 59.22% from the current stock price of 46.28.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRSP stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 9 | 9 | 9 | 9 | 9 | 9 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 19 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $53 | Hold | Reiterates | $53 | +14.52% | Nov 6, 2024 |
| Barclays | Barclays | Hold Maintains $59 → $55 | Hold | Maintains | $59 → $55 | +18.84% | Nov 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $84 | Strong Buy | Reiterates | $84 | +81.50% | Nov 6, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $60 → $53 | Hold | Maintains | $60 → $53 | +14.52% | Oct 4, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $120 → $100 | Strong Buy | Maintains | $120 → $100 | +116.07% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
25.15M
from 371.21M
Decreased by -93.22%
Revenue Next Year
157.52M
from 25.15M
Increased by 526.27%
EPS This Year
-5.26
from -1.94
EPS Next Year
-5.15
from -5.26
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 213.1M | 692.6M | 5.7B | ||
| Avg | 25.2M | 157.5M | 770.6M | ||
| Low | 1.6M | n/a | 19.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -42.6% | 2,653.6% | 3,528.1% | ||
| Avg | -93.2% | 526.3% | 389.2% | ||
| Low | -99.6% | - | -87.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.16 | -3.29 | 8.47 | ||
| Avg | -5.26 | -5.15 | -3.04 | ||
| Low | -6.56 | -6.71 | -7.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.